Redeye revisits its market share assumptions for BONESUPPORT’s extremities business. We argue that the company’s products are likely to be strong contenders to the standard of care, opting for increased market share assumptions, rendering an updated fair value range. In the near term, we identify several key catalysts to support the strong share price momentum.

https://www.redeye.se/research/996347/bonesupport-leading-an-ongoing-paradigm-shift?utm_source=finwire&utm_medium=RSS

Redeye